A prospective observational study of osimertinib as predictive marker against patients with EGFR T790M-positive NSCLC.
Not Applicable
- Conditions
- ung Cancer
- Registration Number
- JPRN-UMIN000027233
- Lead Sponsor
- Gunma University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Exclusion Criteria
1)Active double cancer 2)Interstitial pneumonitis on chest CT 3)Symptomatic brain metastases 4)Uncontrollable pleural effusion or pericardial effusion 5)Active infectious disease 6)No allogeneic bone marrow transplant
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoint:To predict the efficacy of osimertinib according to quantitative amount of T790M expression. Secandary endpoint:To predict the efficacy of osimertinib according to quantitative amount of C797S.
- Secondary Outcome Measures
Name Time Method